joint space narrowing; osteoarthritis; strontium ranelate; symptoms; treatment
Abstract :
[en] Osteoarthritis is a primary cause of disability and functional incapacity. Pharmacological treatment is currently limited to symptomatic management, and in advanced stages, surgery remains the only solution. The therapeutic armamentarium for osteoarthritis remains poor in treatments with an effect on joint structure, that is, disease-modifying osteoarthritis drugs (DMOADs). Glucosamine sulfate and chondroitin sulfate are the only medications for which some conclusive evidence for a disease-modifying effect is available. Strontium ranelate is currently indicated for the prevention of fracture in severe osteoporosis. Its efficacy and safety as a DMOAD in knee osteoarthritis has recently been explored in the SEKOIA trial, a 3-year randomized, double-blind, placebo-controlled trial. Outpatients with knee osteoarthritis, Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) of 2.5-5 mm received strontium ranelate 1 g/day (n = 558) or 2 g/day (n = 566), or placebo (n = 559). This sizable population was aged 62.9 years and had a JSW of 3.50 +/- 0.84 mm. Treatment with strontium ranelate led to significantly less progression of knee osteoarthritis: estimates for annual difference in joint space narrowing versus placebo were 0.14 mm [95% confidence interval (CI) 0.05-0.23 mm; p < 0.001] for 1 g/day and 0.10 mm (95% CI 0.02-0.19 mm; p = 0.018) for 2 g/day, with no difference between strontium ranelate groups. Radiological progression was less frequent with strontium ranelate (22% with 1 g/day and 26% with 2 g/day versus 33% with placebo, both p < 0.05), as was radioclinical progression (8% and 7% versus 12%, both p < 0.05). Symptoms also improved with strontium ranelate 2 g/day only in terms of total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score (p = 0.045), and its components for pain (p = 0.028) and physical function (p = 0.099). Responder analyses using a range of criteria for symptoms indicated that the effect of strontium ranelate 2 g/day on pain and physical function was clinically meaningful. Strontium ranelate was well tolerated. The observation of both structure and symptom modification with strontium ranelate 2 g/day makes SEKOIA a milestone in osteoarthritis research and treatment.
Disciplines :
General & internal medicine
Author, co-author :
REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
NEUPREZ, Audrey ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence.
Publication date :
2013
Journal title :
Therapeutic Advances in Musculoskeletal Disease
ISSN :
1759-720X
eISSN :
1759-7218
Publisher :
SAGE Publications, New York, United States - New York
Alexandersen P. Karsdal M. Byrjalsen I. Christiansen C. (2011) Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 14: 236–243.
Alexandersen P. Karsdal M. Qvist P. Reginster J. Christiansen C. (2007) Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 40: 218–222.
Altman R. Asch E. Bloch D. Bole G. Borenstein D. Brandt K. et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29: 1039–1049.
Atkins G. Welldon K. Halbout P. Findlay D. (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653–664.
Bellamy N. Bell M. Goldsmith C. Pericak D. Walker V. Raynauld J. et al (2005) Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 64: 881–885.
Bellamy N. Buchanan W. Goldsmith C. Campbell J. Stitt L. (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15: 1833–1840.
Bijlsma J. Berenbaum F. Lafeber F. (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377: 2115–2126.
Brennan T. Rybchyn M. Green W. Atwa S. Conigrave A. Mason R. (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157: 1291–1300.
Bruyère O. Delferriere D. Roux C. Wark J. Spector T. Devogelaer J. et al (2008) Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 67: 335–339.
Bruyère O. Richette P. Bellamy N. Brown J. Chapurlat R. Chevalier X. et al (2013) Strontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee osteoarthritis – the SEKOIA study. Osteoporos Int 24(Suppl. 1): OC27.
Chang W. Tu C. Chen T. Komuves L. Oda Y. Pratt S. et al (1999) Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140: 5883–5893.
Chattopadhyay N. Quinn S. Kifor O. Ye C. Brown E. (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 74: 438–447.
Conaghan P. Hunter D. Maillefert J. Reichmann W. Losina E. (2011) Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 19: 606–610.
Cooper C. Berenbaum F. Nash P. Zamani O. Cohen-Solal M. Bianchi G. et al (2013) Strontium ranelate prevents radiological progression in patients with primary knee osteoarthritis. Osteoporos Int 24(Suppl. 1): P581.
Cooper C. Reginster J. Chapurlat R. Christiansen C. Genant H. Bellamy N. et al (2012) Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of a randomised double-blind, placebo-controlled trial. Curr Med Res Opin 28: 231–239.
Ehrich E. Davies G. Watson D. Bolognese J. Seidenberg B. Bellamy N. (2000) Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 27: 2635–2641.
European Medicines Agency (2010) Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. Available at: http://www.ema.europa.eu (accessed 25 May 2013).
Felson D. Chaisson C. Hill C. Totterman S. Gale M. Skinner K. et al (2001) The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 134: 541–549.
Felson D. Niu J. Guermazi A. Roemer F. Aliabadi P. Clancy M. et al (2007) Correlation of the development of knee pain with enlarging bone marrow lesions on magnetic resonance imaging. Arthritis Rheum 56: 2986–2992.
Findlay D. (2007) Vascular pathology and osteoarthritis. Rheumatology (Oxford) 46: 1763–1768.
Gensburger D. Arlot M. Sornay-Rendu E. Roux J. Delmas P. (2009) Radiologic assessment of age-related knee joint space changes in women: a 4-year longitudinal study. Arthritis Rheum 61: 336–343.
Gulhan I. Bilgili S. Gunaydin R. Gulhan S. Posaci C. (2008) The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study. Arch Gynecol Obstet 278: 437–441.
Henrotin Y. Labasse A. Zheng S. Galais P. Tsouderos Y. Crielaard J. et al (2001) Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 16: 299–308.
Hiligsmann M. Reginster J. (2013) The economic weight of osteoarthritis in Europe. Medicographia 35: 197–202.
Hochberg M. (2012) Osteoarthritis year 2012 in review: clinical. Osteoarthritis Cartilage 20: 1465–1469.
Jordan J. Helmick C. Renner J. Luta G. Dragomir A. Woodard J. et al (2007) Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol 34: 172–180.
Karsdal M. Leeming D. Dam E. Henriksen K. Alexandersen P. Pastoureau P. et al (2008) Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 16: 638–646.
Kaufman J. Audran M. Bianchi G. Braga V. Diaz-Curiel M. Francis R. et al (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98: 592–601.
Kellgren J. Lawrence J. (1963) The Epidemiology of Chronic Rheumatism: Atlas of Standard Radiographs, 2nd edition. Oxford, UK: Blackwell Scientific.
Kothari M. Guermazi A. von Ingersleben G. Miaux Y. Sieffert M. Block J. et al (2004) Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol 14: 1568–1573.
Kwan T. Lajeunesse D. Pelletier J. Martel-Pelletier J. (2010) Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 24: 51–70.
Lafeber F. van Laar J. (2013) Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann Rheum Dis 72: 157–161.
Lane N. Brandt K. Hawker G. Peeva E. Schreyer E. Tsuji W. et al (2011) OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage 19: 478–482.
Lane N. Nevitt M. Genant H. Hochberg M. (1993) Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J Rheumatol 20: 1911–1918.
Lo G. McAlindon T. Niu J. Zhang Y. Beals C. Dabrowski C. et al (2009) Bone marrow lesions and joint effusion are strongly and independently associated with weight-bearing pain in knee osteoarthritis: data from the osteoarthritis initiative. Osteoarthritis Cartilage 17: 1562–1569.
Marie P. (2007) Strontium ranelate: New insights into its dual mode of action. Bone 40: S5-S8.
Meunier P. Roux C. Seeman E. Ortolani S. Badurski J. Spector T. et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–468.
Narmazi H. Cooper C. Reginster J. (2012) Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial: Letter to the Editor and Author's response. Curr Med Res Opin 28: 609–610.
Neogi T. (2012) Clinical significance of bone changes in osteoarthritis. Ther Adv Musculoskelet Dis 4: 259–267.
Nuesch E. Dieppe P. Reichenbach S. Williams S. Iff S. Juni P. (2011) All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 342: d1165.
Peterfy C. Guermazi A. Zaim S. Tirman P. Miaux Y. White D. et al (2004) Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 12: 177–190.
Pham T. van der Heijde D. Altman R. Anderson J. Bellamy N. Hochberg M. et al (2004) OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 12: 389–399.
Picavet H. van Gils H.W.V. Schouten J. (2000) Musculoskeletal complaints in the Dutch population: prevalences, consequences, and risk groups [in Dutch]. Bilthoven, The Netherlands: CBS/RIVM. RIVM report number: 266807002.
Reginster J. Badurski J. Bellamy N. Bensen W. Chapurlat R. Chevalier X. et al (2013 a) Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 72: 179–186.
Reginster J. Kaufman J. Goemaere S. Devogelaer J. Benhamou C. Felsenberg D. et al (2011) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23: 1115–1122.
Reginster J. Pelousse F. Bruyère O. (2013 b) Is there potential for strontium ranelate in the management of osteoarthritis? Clin Pract 10: 201–207.
Reginster J. Seeman E. de Vernejoul M. Adami S. Compston J. Phenekos C. et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90: 2816–2822.
Reichmann W. Maillefert J. Hunter D. Katz J. Conaghan P. Losina E. (2011) Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review. Osteoarthritis Cartilage 19: 550–556.
Tat S. Lajeunesse D. Pelletier J. Martel-Pelletier J. (2010) Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 24: 51–70.
Tat S. Pelletier J. Mineau F. Caron J. Martel-Pelletier J. (2011) Strontium ranelate inhibits key factors affecting bone remodelling in human osteoarthritic subchondral bone osteoblasts. Bone 49: 559–567.
Tubach F. Ravaud P. Baron G. Falissard B. Logeart I. Bellamy N. et al (2005) Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 64: 29–33.
US Food and Drug Administration (1999) Guidance for industry. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis. http://www.fda.gov (accessed 27 May 2013).
van Dijk G. Veenhof C. Schellevis F. Hulsmans H. Bakker J. Arwert H. et al (2008) Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 9: 95.
van Saase J. van Romunde L. Cats A. Vandenbroucke J. Valkenburg H. (1989) Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 48: 271–280.
Yusuf E. Kortekaas M. Watt I. Huizinga T. Kloppenburg M. (2011) Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 70: 60–67.
Zhang W. Nuki G. Moskowitz R. Abramson S. Altman R. Arden N. et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18: 476–499.
